|
GB1351025A
(en)
*
|
1971-08-20 |
1974-04-24 |
Aron Md Samuel J |
Oxadiazol-5-yl biguanide derivatives method for their preparation and pharmaceutical compositions containing them
|
|
ZA876930B
(en)
|
1986-10-07 |
1988-05-25 |
Hoffmann La Roche |
Pharmaceutical compositions
|
|
IT1245890B
(it)
|
1991-04-12 |
1994-10-25 |
Alfa Wassermann Spa |
Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
|
|
GB9203347D0
(en)
*
|
1992-02-17 |
1992-04-01 |
Wellcome Found |
Hypolipidaemic compounds
|
|
US5234697A
(en)
|
1992-06-22 |
1993-08-10 |
Digestive Care Inc. |
Compositions of gastric acid-resistant microspheres containing salts of bile acids
|
|
US5415872A
(en)
*
|
1992-06-22 |
1995-05-16 |
Digestive Care Inc. |
Compositions of gastric acid-resistant microspheres containing salts of bile acids
|
|
IL108633A
(en)
*
|
1993-02-15 |
1998-07-15 |
Wellcome Found |
History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
|
|
IL108634A0
(en)
*
|
1993-02-15 |
1994-05-30 |
Wellcome Found |
Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
|
|
KR970005178B1
(ko)
|
1993-12-28 |
1997-04-14 |
이승철 |
피로회복제 조성물
|
|
US5589358A
(en)
*
|
1993-12-29 |
1996-12-31 |
Univ Wake Forest |
Ileal bile acid transporter compositions and methods
|
|
ZA956647B
(en)
*
|
1994-08-10 |
1997-02-10 |
Wellcome Found |
Hypolipidaemic compounds.
|
|
US6268392B1
(en)
*
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
|
US5994391A
(en)
*
|
1994-09-13 |
1999-11-30 |
G.D. Searle And Company |
Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US6107494A
(en)
*
|
1994-09-13 |
2000-08-22 |
G.D. Searle And Company |
Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US6642268B2
(en)
*
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
|
US6262277B1
(en)
*
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
GB9423172D0
(en)
*
|
1994-11-17 |
1995-01-04 |
Wellcom Foundation The Limited |
Hypolipidemic benzothiazepines
|
|
US6861053B1
(en)
|
1999-08-11 |
2005-03-01 |
Cedars-Sinai Medical Center |
Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
|
|
NZ331813A
(en)
|
1996-03-11 |
2001-03-30 |
G |
Benzothiepine compounds having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
DE19616486C5
(de)
*
|
1996-04-25 |
2016-06-30 |
Royalty Pharma Collection Trust |
Verfahren zur Senkung des Blutglukosespiegels in Säugern
|
|
US5908830A
(en)
*
|
1996-10-31 |
1999-06-01 |
Merck & Co., Inc. |
Combination therapy for the treatment of diabetes and obesity
|
|
GB9704208D0
(en)
|
1997-02-28 |
1997-04-16 |
Glaxo Group Ltd |
Chemical compounds
|
|
DE69815180T2
(de)
*
|
1997-03-14 |
2004-04-29 |
Aventis Pharma Deutschland Gmbh |
Hypolipidemische 1,4-Benzothiazepin-1,1-dioxide
|
|
US5900233A
(en)
*
|
1997-10-16 |
1999-05-04 |
Day; Charles E. |
Epichlorohydrin and 1-(3-aminopropyl) imidazole copolymer and its use in treating irritable bowel syndrome
|
|
US6369220B1
(en)
*
|
1997-12-19 |
2002-04-09 |
Jinglin (James T.) Li |
Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides
|
|
GB9800428D0
(en)
*
|
1998-01-10 |
1998-03-04 |
Glaxo Group Ltd |
Chemical compounds
|
|
AU766219B2
(en)
*
|
1998-02-02 |
2003-10-09 |
1149336 Ontario Inc. |
Method of regulating glucose metabolism, and reagents related thereto
|
|
JP2000026300A
(ja)
|
1998-07-02 |
2000-01-25 |
Pola Chem Ind Inc |
血管内皮細胞保護医薬組成物
|
|
PL348508A1
(en)
*
|
1998-12-23 |
2002-05-20 |
Searle Llc |
Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
|
|
SE9901387D0
(sv)
|
1999-04-19 |
1999-04-19 |
Astra Ab |
New pharmaceutical foromaulations
|
|
US6309663B1
(en)
*
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
|
TR200002099A3
(tr)
*
|
1999-07-22 |
2001-06-21 |
Sankyo Company Limited |
Siklobüten türevleri, bunlarin hazirlanmasi ve terapötik kullanimlari
|
|
PT1741446E
(pt)
|
2000-01-21 |
2008-05-09 |
Novartis Pharma Ag |
Combinações incluindo inibidores da dipeptidilpeptidase-iv e agentes anti-diabéticos
|
|
SE0000772D0
(sv)
*
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2001077325A1
(fr)
|
2000-04-12 |
2001-10-18 |
Takeda Chemical Industries, Ltd. |
Nouvelle proteine de recepteur couple aux proteines g et adn de celle-ci
|
|
US20020183307A1
(en)
*
|
2000-07-26 |
2002-12-05 |
Tremont Samuel J. |
Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
|
|
NZ523684A
(en)
*
|
2000-07-28 |
2005-04-29 |
F |
New pharmaceutical composition
|
|
US20030153513A1
(en)
*
|
2000-08-01 |
2003-08-14 |
Teruo Shiomi |
Preventives or remedies for obesity or fatty liver
|
|
US7198914B2
(en)
|
2000-11-17 |
2007-04-03 |
Banyu Pharmaceutical Co., Ltd. |
Guanosine triphosphate (GTP)-binding protein-coupled receptor protein, BG37
|
|
EG26979A
(en)
*
|
2000-12-21 |
2015-03-01 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2002053548A1
(fr)
*
|
2000-12-27 |
2002-07-11 |
Banyu Pharmaceutical Co.,Ltd. |
Derives de la benzothiazepine
|
|
WO2002078625A2
(en)
|
2001-03-28 |
2002-10-10 |
Pharmacia Corporation |
Therapeutic combinations for cardiovascular and inflammatory indications
|
|
UA76475C2
(en)
*
|
2001-07-19 |
2006-08-15 |
Pharmacia Corp |
Combination of eplerenon and hmg co-a reductase inhibitor and its use for treatment and/or prophylaxis of pathologic condition in cardiovascular system
|
|
NZ531293A
(en)
|
2001-08-22 |
2005-08-26 |
Aventis Pharma Gmbh |
Pharamceuticals containing 1,4-benzothiepine-1,1-dioxide derivatives and another active substances such as ezetimibe, pamaqueside or tiqueside for treating lipid metabolism and atherosclerotic disorders
|
|
GB0121337D0
(en)
*
|
2001-09-04 |
2001-10-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121622D0
(en)
*
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121621D0
(en)
*
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
TWI331143B
(en)
*
|
2001-09-08 |
2010-10-01 |
Astrazeneca Uk Ltd |
Benzothiadiazepine derivatives, process for preparing them, and pharmaceutical composition comprising them
|
|
WO2003028632A2
(en)
|
2001-10-01 |
2003-04-10 |
Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The |
Development of a preventive vaccine for filovirus infection in primates
|
|
MXPA04003524A
(es)
*
|
2001-11-02 |
2004-07-23 |
Searle Llc |
Compuestos de benzotiepina monofluorados y difluorados novedosos como inhibidores de transporte de acido biliar co-dependiente de sodio apical (asbt) y captacion de taurocolato.
|
|
GB0229931D0
(en)
*
|
2002-12-21 |
2003-01-29 |
Astrazeneca Ab |
Therapeutic agents
|
|
BR0306643A
(pt)
*
|
2002-01-17 |
2004-10-19 |
Pharmacia Corp |
Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical
|
|
GB0201850D0
(en)
*
|
2002-01-26 |
2002-03-13 |
Astrazeneca Ab |
Therapeutic treatment
|
|
US20040014806A1
(en)
*
|
2002-03-08 |
2004-01-22 |
Pharmacia Corporation |
Methods and compositions for lowering levels of blood lipids
|
|
GB0209467D0
(en)
*
|
2002-04-25 |
2002-06-05 |
Astrazeneca Ab |
Chemical compounds
|
|
JP2005531570A
(ja)
*
|
2002-05-23 |
2005-10-20 |
ユーエムディー， インコーポレイテッド |
貫粘膜薬物送達及び凍結保護のための組成物及び方法
|
|
AU2003257578B2
(en)
|
2002-08-28 |
2009-01-22 |
Asahi Kasei Pharma Corporation |
Novel quaternary ammonium compounds
|
|
US7312208B2
(en)
*
|
2002-08-28 |
2007-12-25 |
Asahi Kasei Pharma Corporation |
Quaternary ammonium compounds
|
|
US20040122033A1
(en)
*
|
2002-12-10 |
2004-06-24 |
Nargund Ravi P. |
Combination therapy for the treatment of obesity
|
|
US20040138145A1
(en)
|
2002-12-12 |
2004-07-15 |
Aventis Pharma S.A. |
Application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of alzheimer's disease
|
|
GB0304194D0
(en)
*
|
2003-02-25 |
2003-03-26 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0307918D0
(en)
*
|
2003-04-05 |
2003-05-14 |
Astrazeneca Ab |
Therapeutic use
|
|
EP1635832A2
(en)
*
|
2003-06-06 |
2006-03-22 |
Merck & Co., Inc. |
Combination therapy for the treatment of diabetes
|
|
JP2005097216A
(ja)
|
2003-09-26 |
2005-04-14 |
Kaneka Corp |
ＰＰＡＲγリガンド剤
|
|
CN102293773A
(zh)
*
|
2004-02-27 |
2011-12-28 |
旭化成制药株式会社 |
含有苯并硫氮杂卓和苯并虑平化合物的药物
|
|
CN101056656A
(zh)
|
2004-09-15 |
2007-10-17 |
哈佛大学校长及研究员协会 |
在治疗肥胖症和糖尿病中降低er应力
|
|
EP1810689A4
(en)
*
|
2004-10-15 |
2009-07-22 |
Mitsubishi Tanabe Pharma Corp |
MEANS FOR THE PREVENTION AND / OR TREATMENT OF DIABETES
|
|
US20090253752A1
(en)
|
2004-10-25 |
2009-10-08 |
Bryan Burkey |
Combination of dpp-iv inhibitor, ppar antidiabetic and metmorfin
|
|
CA2588168A1
(en)
|
2004-11-24 |
2006-06-01 |
Seo Hong Yoo |
Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
|
|
US20070032420A1
(en)
*
|
2005-02-09 |
2007-02-08 |
Entelos, Inc. |
Treating diabetes with glucagon-like peptide-1 secretagogues
|
|
US20060193895A1
(en)
*
|
2005-02-25 |
2006-08-31 |
Use-Techno Corporation |
Additive for food and beverage, pharmaceutical composition, GLUT4 translocator, and method for translocating GLUT4
|
|
FR2883284A1
(fr)
|
2005-03-15 |
2006-09-22 |
Commissariat Energie Atomique |
Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux
|
|
US20060222709A1
(en)
*
|
2005-03-18 |
2006-10-05 |
Agi Therapeutics Research Ltd. |
Metformin methods and formulations for treating chronic constipation
|
|
PE20061245A1
(es)
|
2005-03-30 |
2007-01-06 |
Generex Pharm Inc |
Composiciones para la transmision transmucosa oral de la metformina
|
|
US20080031968A1
(en)
*
|
2005-04-01 |
2008-02-07 |
The Brigham And Women's Hospital, Inc. |
Methods for increasing cellular energy expenditure
|
|
WO2006105912A2
(en)
|
2005-04-04 |
2006-10-12 |
Julius-Maximilians-Universität Würzburg |
Peptides that down regulate the activity of plasma membrane transporters including sodium-d-glucose cotransporter sglt1
|
|
AU2006231071B2
(en)
|
2005-04-04 |
2012-09-06 |
Julius-Maximilians-Universitaet Wuerzburg |
Tripeptides that down regulate the activity of plasma membrane transporters including sodium-D-glucose cotransporter SGLT1
|
|
WO2006116814A1
(en)
|
2005-05-02 |
2006-11-09 |
Vanadis Bioscience Ltd |
Composition and uses thereof
|
|
US20070025953A1
(en)
*
|
2005-07-27 |
2007-02-01 |
Jones Michael R |
Co-therapy for diabetic conditions
|
|
RU2008116578A
(ru)
|
2005-09-30 |
2009-11-10 |
Новартис АГ (CH) |
Применение ингибиторов dpp-iv для лечения аутоиммунных заболеваний и отторжения трансплантата
|
|
WO2007076260A2
(en)
*
|
2005-12-19 |
2007-07-05 |
Smithkline Beecham Corporation |
Farnesoid x receptor agonists
|
|
CN101404987A
(zh)
|
2006-01-20 |
2009-04-08 |
史密丝克莱恩比彻姆公司 |
磺酰胺衍生物在治疗代射和神经系统疾病中的用途
|
|
CN101395170A
(zh)
|
2006-02-14 |
2009-03-25 |
英特塞普特药品公司 |
用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物
|
|
US7932244B2
(en)
|
2006-06-27 |
2011-04-26 |
Intercept Pharmaceuticals, Inc. |
Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
|
|
US20080065136A1
(en)
*
|
2006-08-30 |
2008-03-13 |
Andrew Young |
Distender device and method for treatment of obesity and metabolic and other diseases
|
|
CL2007003035A1
(es)
*
|
2006-10-24 |
2008-05-16 |
Smithkline Beechman Corp |
Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
|
|
JP2010509252A
(ja)
*
|
2006-11-14 |
2010-03-25 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
改善された特性を有する新規な１，４−ベンゾチエピン−１，１−ジオキシド誘導体、それらの製造方法、上記化合物を含有する薬物、及びそれらの使用
|
|
DE102006053635B4
(de)
|
2006-11-14 |
2011-06-30 |
Sanofi-Aventis Deutschland GmbH, 65929 |
Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
|
WO2008067219A2
(en)
|
2006-11-29 |
2008-06-05 |
Kalypsys, Inc. |
Quinazolinone modulators of tgr5
|
|
KR101555716B1
(ko)
|
2007-01-19 |
2015-09-25 |
인터셉트 파마슈티컬즈, 인크. |
Ｔｇｒ5 조절제로서의 23-치환 담즙산 및 이의 사용 방법
|
|
WO2008097976A1
(en)
*
|
2007-02-09 |
2008-08-14 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
MX2010002027A
(es)
*
|
2007-08-23 |
2010-03-15 |
Theracos Inc |
Derivados de bencilbenceno y metodos de uso.
|
|
DK2698375T3
(en)
|
2008-11-19 |
2018-05-28 |
Intercept Pharmaceuticals Inc |
TGR5 modulators and methods for using them
|
|
JP2012509892A
(ja)
*
|
2008-11-26 |
2012-04-26 |
サティオゲン ファーマシューティカルズ，インク． |
サティオゲン類を含有する組成物及び使用の方法
|
|
CA2744817C
(en)
|
2008-11-26 |
2020-07-07 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of obesity and diabetes
|
|
US20110065676A1
(en)
|
2009-06-24 |
2011-03-17 |
Schering Corporation |
Combination therapies comprising par1 antagonists with nar agonists
|
|
EP2575821B1
(en)
|
2010-05-26 |
2015-08-12 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
|
|
PL3400944T3
(pl)
|
2010-11-04 |
2020-11-16 |
Albireo Ab |
Inhibitory ibat w leczeniu chorób wątroby
|
|
MX2013005110A
(es)
|
2010-11-08 |
2013-08-21 |
Albireo Ab |
Inhibidores del ibat para el tratamiento de padecimientos metabolicos y condiciones relacionadas.
|
|
JP6097695B2
(ja)
|
2010-11-08 |
2017-03-15 |
アルビレオ アクチエボラグ |
Ｉｂａｔ阻害剤および胆汁酸結合剤を含む薬学的組み合わせ
|